ASSOCIATION OF SLEEP DURATION WITH COGNITION AND VASCULAR BRAIN INJURY MODERATED BY HYPERTENSIVE STATUS High blood pressure and shorter sleep may worsen brain decline: study
With
Dr Stephanie Yiallourou, Senior Research Fellow
Turner Institute for Brain & Mental Health, Monash University
Melbourne, Australia
Associate Professor Matthew Pase
Turner Institute for Brain & Mental Health, Monash University
Melbourne, Australia
CASE STUDY
Filmed in Melbourne, Australia| May 2025
People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.
Published in the Journal of the American Heart Association, researchers assessed whether the combined effect of hypertension and short sleep duration had a negative impact on brain health.
They used data from 682 dementia-free Framingham Heart Study participants who completed overnight sleep recordings, self-reported sleep duration questionnaires, blood pressure and cognitive assessments; 637 underwent brain magnetic resonance imaging (MRI).
In those with high blood pressure, shorter sleep duration was associated with poorer executive functioning and markers of brain injury and accelerated brain ageing on MRI. These associations were not observed in people with normal blood pressure.
These results were similar following adjustment for genetic, clinical and demographic variables.
Insufficient sleep is generally defined as less than seven hours. Participants reported sleeping an average of seven hours per night, with 32 percent reporting a short sleep duration of less than six hours per night.
Moderate to severe obstructive sleep apnoea was identified in 16 per cent of individuals, and almost one‐quarter of the overall sample reported using sleeping pills regularly.
“In individuals with hypertension, shorter sleep duration was associated with worse cognitive performance and greater brain injury,” the study found.
“Inadequate sleep has been linked to hypertension and dementia, and though the underlying mechanisms remain unclear, it is possible that short sleep and hypertension interact to increase the risk of cognitive impairment and vascular brain injury.”
While the cohort was based in the US, researchers believe the results would be similar in Australia.
Senior author Associate Professor Matthew Pase, from the Monash University School of Psychological Sciences and Turner Institute for Brain and Mental Health, said short sleep duration was already associated with an increased risk of cognitive impairment and dementia.
He said while short sleep was associated with elevated blood pressure, the combination of short sleep and hypertension on brain health was unclear before this study.
“These findings have significance, given that over one-third of Australians experience sleep problems,” Associate Professor Pase said. “Importantly, sleep problems and hypertension are treatable. Addressing these factors may offer new opportunities for intervention to improve brain health.”
First author Dr Stephanie Yiallourou, from the Monash University School of Psychological Sciences and Turner Institute for Brain and Mental Health, said screening people with high blood pressure for insufficient sleep could allow tailored therapies to improve brain aging and reduce brain injury.
Dr Yiallourou said they could also be targeted for new randomised controlled trials to determine the efficacy of sleep treatments and blood pressure–lowering therapies in preventing or delaying cognitive impairment.
“The next step in this research is to explore whether the double hit of short sleep and hypertension is associated with dementia risk in the long-term,” she said.
This work was supported by an Alzheimer’s Association Grant.
Source: Monash University Media Release
-
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Dental care improvements using informatics and artificial intelligence
a member of the Scientific Advisory Committee for Dentroid, a startup in Australia aiming to revolutionise dentistry with laser technology. He has gained extensive experience in various roles at research-intensive institutions across three different continents.
